News
ESLAW
0.0788
0.00%
0.0000
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2d ago
Weekly Report: what happened at ESLA last week (0706-0710)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 07/07 12:05
Weekly Report: what happened at ESLA last week (0629-0703)?
Weekly Report · 07/06 10:06
Estrella Immunopharma Shareholders Ratify 2026 Auditor Appointment
TipRanks · 06/30 21:54
Estrella Immunopharma holds annual stockholders meeting via virtual webcast
PUBT · 06/30 21:30
Weekly Report: what happened at ESLA last week (0622-0626)?
Weekly Report · 06/29 10:02
Weekly Report: what happened at ESLA last week (0615-0619)?
Weekly Report · 06/22 10:09
Weekly Report: what happened at ESLA last week (0608-0612)?
Weekly Report · 06/15 10:10
Weekly Report: what happened at ESLA last week (0601-0605)?
Weekly Report · 06/08 10:07
Weekly Report: what happened at ESLA last week (0525-0529)?
Weekly Report · 06/01 10:10
Estrella Immunopharma announces annual shareholder meeting
PUBT · 05/27 21:26
Weekly Report: what happened at ESLA last week (0518-0522)?
Weekly Report · 05/25 10:13
Estrella Immunopharma Q1 EPS $(0.05) Beats $(0.18) Estimate
Benzinga · 05/18 13:57
Estrella Immunopharma, Inc. Reports Financial Results for the Quarter Ended March 31, 2026
Press release · 05/18 12:11
Weekly Report: what happened at ESLA last week (0511-0515)?
Weekly Report · 05/18 10:13
Estrella Immunopharma Q1 net loss widens to $2.3 million from year-ago quarter
PUBT · 05/18 10:05
Estrella Immunopharma delays quarterly report filing on administrative delay
PUBT · 05/18 10:04
Weekly Report: what happened at ESLA last week (0504-0508)?
Weekly Report · 05/11 10:11
Estrella Immunopharma to join D. Boral Capital Global Conference investor meetings
PUBT · 05/05 12:02
More
Webull provides a variety of real-time ESLAW stock news. You can receive the latest news about Estrella Immunopharma through multiple platforms. This information may help you make smarter investment decisions.
About ESLAW
Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.